晚期肝细胞癌的免疫联合治疗：塑造一线治疗方向 - Suppr

Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.

作者信息

Rizzo Alessandro, Ricci Angela Dalia, Brandi Giovanni

机构信息

Department of Experimental, Diagnostic & Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, 40138, Italy.

出版信息

Future Oncol. 2021 Mar;17(7):755-757. doi: 10.2217/fon-2020-0986. Epub 2021 Jan 29.

DOI:10.2217/fon-2020-0986

PMID:33508960

Abstract

摘要

相似文献

Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.

Future Oncol. 2021 Mar;17(7):755-757. doi: 10.2217/fon-2020-0986. Epub 2021 Jan 29.

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.

Front Immunol. 2021 Mar 15;12:652007. doi: 10.3389/fimmu.2021.652007. eCollection 2021.

Pursuing efficacious systemic therapy for hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):95-96. doi: 10.1038/s41575-020-00405-1.

Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.

Medicine (Baltimore). 2021 Jun 25;100(25):e26471. doi: 10.1097/MD.0000000000026471.

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.

Front Immunol. 2021 Mar 30;12:652172. doi: 10.3389/fimmu.2021.652172. eCollection 2021.

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).

Gastroenterology. 2021 Sep;161(3):879-898. doi: 10.1053/j.gastro.2021.06.008. Epub 2021 Jun 12.

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.

Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021.

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.

Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.

Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.

Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.

Clin Liver Dis. 2020 Nov;24(4):739-753. doi: 10.1016/j.cld.2020.07.007. Epub 2020 Sep 2.

引用本文的文献

Integrating Bulk and Single-Cell RNA Sequencing Data Reveals the Prognostic Significance of HOXC9-Related Immune Gene Signatures in Hepatocellular Carcinoma.

Onco Targets Ther. 2025 Mar 29;18:453-465. doi: 10.2147/OTT.S509625. eCollection 2025.

Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate.

Pathobiology. 2025;92(3):157-168. doi: 10.1159/000543933. Epub 2025 Mar 4.

Unraveling the therapeutic potential of Calculus Bovis in liver cancer: A novel step for targeted cancer treatment.

World J Gastroenterol. 2025 Jan 21;31(3):99358. doi: 10.3748/wjg.v31.i3.99358.

Transarterial Chemoembolization Combined with Microwave Ablation in Elderly Patients with Recurrent Medium or Large Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2024 Oct 22;11:2005-2017. doi: 10.2147/JHC.S455411. eCollection 2024.

Advancements in nutritional diagnosis and support strategies during the perioperative period for patients with liver cancer.

World J Gastrointest Surg. 2024 Aug 27;16(8):2409-2425. doi: 10.4240/wjgs.v16.i8.2409.

Feasibility and Safety of the Clinical Outcomes of TACE Combined with Lenvatinib and PD-1 Blockades in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Exploratory Study.

Int J Gen Med. 2024 Aug 21;17:3627-3640. doi: 10.2147/IJGM.S473676. eCollection 2024.

Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.

BMC Cancer. 2024 Aug 19;24(1):1023. doi: 10.1186/s12885-024-12780-y.

inhibits M2 tumor-associated macrophage polarization Wnt/β-catenin pathway modulation to suppress liver cancer.

World J Gastroenterol. 2024 Aug 7;30(29):3511-3533. doi: 10.3748/wjg.v30.i29.3511.

Optimizing the resveratrol fragments for novel in silico hepatocellular carcinoma de novo drug design.

Sci Rep. 2024 Jul 28;14(1):17336. doi: 10.1038/s41598-024-68403-w.

Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.

Cancer Commun (Lond). 2024 Sep;44(9):1018-1041. doi: 10.1002/cac2.12595. Epub 2024 Jul 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献